Compare GSK plc (GSK) vs Prudential PLC (PUK) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

Prudential PLC (PUK) trades at $28.59, showing stable daily performance with no change. The stock exhibits a bullish technical signal, supported by strong moving averages. Fundamentally, the company demonstrates robust profitability with a net income margin of 14.52% and ROE of 21.15%, while recent earnings beats in Q4 2025 and Q2 2025 highlight operational strength. Revenue has grown from $16.21B in 2024 to a projected $27.4B in 2025, though challenges persist in key markets like Japan.

The outlook for PUK is cautiously optimistic, driven by earnings growth and strategic expansions in Asia. However, risks include regulatory pressures in China and Japan, where sales suspensions could impact near-term performance. Analyst consensus leans bullish with 50% buy ratings, but investors should monitor geopolitical and regulatory developments that may affect the stock's trajectory.